ARA-290 is a peptide engineered from erythropoietin's structure and investigated in tissue protection and neuropathy. Early clinical evidence is separate from verification of a commercial vial.
What the research shows
A phase 2 report published in 2015 studied people with type 2 diabetes and painful neuropathy, reporting changes in symptoms and selected measurements. The authors called for further evaluation; a specific population and limited follow-up do not establish long-term benefit. [1] [2]
Distinguishing substances and products
ARA-290 should not be used as a synonym for all EPO medicines or described as a blood-cell-boosting product merely because of its structural origin. Related structures do not establish matching indications.
Reading a specific brand’s label
Start with the exact substance and product name, then match the label to the manufacturer’s documents. This article does not establish Thai registration or current availability for an unspecified product.
Frequently asked questions
Is ARA-290 simply EPO for increasing blood cells?
No. The cited research describes a peptide engineered to differ from EPO's blood-forming activity.
Does a phase 2 study validate every brand?
No. Product-specific evidence must match the name, presentation and label.
What information helps identify a specific product?
The brand, product name, full label and matching manufacturer documents. Evidence about the substance alone does not establish a product’s identity, registration or quality.
Related information
For general questions about names or label details, contact LINE: @musclestationth
Sources and review date
Sources checked: 11 September 2026. This page explains selected primary sources; it is not a systematic review of every study.